Skip to search formSkip to main contentSkip to account menu

iclaprim

Known as: 5-[(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl]-2,4-Pyrimidinediamine, 5-[(2RS)-2-Cyclopropyl-7,8-dimethoxy-2H-chromen-5-ylmethyl]pyrimidine-2,4-diamine 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (1)

AR 100

Broader (2)

Folic Acid AntagonistsPyrimidines
Iclaprim:Susc:Pt:Isolate:OrdQnIclaprim:Susc:Pt:Isolate:OrdQn:MIC

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
In vitro and in vivo activity of iclaprim, a diaminopyrimidine compound and potential therapeutic alternative against Pneumocystis pneumonia
Pneumocystis pneumonia is a serious complication that may affect immunosuppressed patients. The absence of reliable and safe… 
2018
2018
Identification of the In Vivo Pharmacokinetics and Pharmacodynamic Driver of Iclaprim
ABSTRACT The neutropenic murine thigh infection model was used to define the pharmacokinetic/pharmacodynamic index linked to… 
Review
2009
Review
2009
Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria.
Review
2009
Review
2009
Iclaprim, a Novel Diaminopyrimidine for the Treatment of Resistant Gram-Positive Infections
Objective To review the pharmacology, microbiology, in vitro susceptibility, pharmacokinetics, clinical trial data, safety, and… 
2009
2009
In Vitro Activity of Iclaprim against Respiratory and Bacteremic Isolates of Streptococcus pneumoniae
ABSTRACT Iclaprim, a novel dihydrofolate reductase inhibitor, inhibited 90% of the clinical isolates (MIC90) of Streptococcus… 
2008
2008
Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.
Arpida Ltd, under license from Roche AG, is developing the diaminopyrimidine dihydrofolate reductase inhibitor iclaprim for the… 
2008
2008
Activity of iclaprim against clinical isolates of Streptococcus pyogenes and Streptococcus agalactiae.
miology of MRSA bacteraemia in the UK. J Antimicrob Chemother 2005; 56: 455–62. 7. Enright MC, Day NP, Davies CE et al… 
2007
2007
Activity of iclaprim against Legionella pneumophila.
larities. A comparison between the TPqnrS-1a-associated QnrS1 protein and the 218-amino-acid proteins from Vibrio splendidus… 
2007
2007
Comparative evaluation of iclaprim potency and bactericidal activity tested against enterococci: Results from the International Study of Iclaprim Susceptibility (ISIS)
Background: Iclaprim (ICL) is a novel diaminopyrimidine, which selectively inhibits bacterial dihydrofolate reductase. Vancomycin… 
2004
2004
In Vitro Activity of a Novel Diaminopyrimidine Compound, Iclaprim, against Chlamydia trachomatis and C. pneumoniae
ABSTRACT The in vitro activities of iclaprim, a novel dihydrofolate reductase inhibitor, azithromycin, and levofloxacin were… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)